VolitionRx Reaches Deal with Hvidovre Hospital, University of Copenhagen for Colorectal Cancer Trials | GenomeWeb

NEW YORK (GenomeWeb News) – VolitionRx today announced an agreement with Hvidovre Hospital, part of the University of Copenhagen in Denmark, covering two clinical trials for colorectal cancer.

As part of the deal, VolitionRx said that it will use data from the trials to support its application for CE marking and a submission to the US Food and Drug Administration for a colorectal cancer test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.